Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Barclays analyst Glen Santangelo has maintained an Overweight rating on Amneal Pharmaceuticals (NASDAQ: AMRX) and raised the price target from $16 to $20. This adjustment reflects a positive outlook for the company in the market.